Delivery strategies of RNA therapeutics to leukocytes

Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various ex...

Full description

Saved in:
Bibliographic Details
Published inJournal of controlled release Vol. 342; pp. 362 - 371
Main Authors Tarab-Ravski, Dana, Stotsky-Oterin, Lior, Peer, Dan
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.02.2022
Subjects
Drug delivery
Leukocytes
mRNA
Nanocarriers
RNA
Drug delivery
mRNA
Leukocytes
RNA
Nanocarriers
Online AccessGet full text

Cover

More Information
Summary:Harnessing RNA-based therapeutics for cancer, inflammation, and viral diseases is hindered by poor delivery of therapeutic RNA molecules. Targeting leukocytes to treat these conditions holds great promise, as they are key participants in their initiation, drug response, and treatment. The various extra- and intra-cellular obstacles that impediment the clinical implementation of therapeutic RNA can be overcome by utilizing drug delivery systems. However, delivery of therapeutic RNA to leukocytes poses an even greater challenge as these cells are difficult to reach and transfect upon systemic administration. This review briefly describes the existing successful delivery strategies that efficiently target leukocytes in vivo and discuss their potential clinical applicability. [Display omitted] •RNA-based therapeutics can target proteins that are considered as "undruggable".•Clinically applying therapeutic RNA to leukocytes remains a significant hurdle.•Various nanocarriers demonstrated efficient delivery of therapeutic RNA in vivo.•Improving delivery systems is crucial to drive more FDA approvals of therapeutic RNA.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
ISSN:0168-3659
1873-4995
DOI:10.1016/j.jconrel.2022.01.016